West Pharmaceutical Services Inc (WST) SEC Filing 8-K Material Event for the period ending Tuesday, February 19, 2019

SEC Filings

West Pharmaceutical Services Inc

CIK: 105770 Ticker: WST

Washington, D.C. 20549


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – February 19, 2019
(Exact name of registrant as specified in its charter)

(State or other jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
530 Herman O. West Drive, Exton, PA
(Address of principal executive offices)
(Zip Code)

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨


Item 7.01 Regulation FD Disclosure.

On February 21, 2019, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that its Board of Directors (the “Board”) has approved a second-quarter 2019 dividend of $0.15 per share. The dividend will be paid on May 1, 2019, to shareholders of record as of April 17, 2019. The Company also announced that its Board authorized a share repurchase program for calendar-year 2019, as described in Item 8.01 below.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 8.01 Other Events.

On February 19, 2019, the Company’s Board authorized a share repurchase program for calendar-year 2019 authorizing the repurchase of up to 800,000 shares of the Company’s common stock from time to time on the open market or in privately-negotiated transactions as permitted under Exchange Act Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The share repurchase program is expected to be completed by December 31, 2019. The Company’s previously-authorized share repurchase program expired on December 31, 2018.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.
West Pharmaceutical Services, Inc. Press Release, dated February 21, 2019.



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President, Chief Financial Officer and Treasurer
February 21, 2019




View differences made from one to another to evaluate West Pharmaceutical Services Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by West Pharmaceutical Services Inc.


Assess how West Pharmaceutical Services Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

West Pharmaceutical Services Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

West Pharmaceutical Services Inc provided additional information to their SEC Filing as exhibits

Ticker: WST
CIK: 105770
Form Type: 8-K Corporate News
Accession Number: 0000105770-19-000008
Submitted to the SEC: Thu Feb 21 2019 9:21:54 AM EST
Accepted by the SEC: Thu Feb 21 2019
Period: Tuesday, February 19, 2019
Industry: Fabricated Rubber Products
  1. Financial Exhibit
  2. Other Events
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: